Upstream Bio (UPB) Projected to Post Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Upstream Bio to post earnings of ($0.56) per share for the quarter.

Upstream Bio Stock Performance

Shares of NASDAQ UPB opened at $7.73 on Wednesday. Upstream Bio has a 12-month low of $6.65 and a 12-month high of $29.46. The business’s fifty day moving average is $12.14.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective on the stock. TD Cowen assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set a “buy” rating on the stock. William Blair assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price objective on the stock.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.